• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

CALR mutation, MPL mutation and triple negativity identify patients with the lowest vascular risk in primary myelofibrosis.

作者信息

Finazzi M C, Carobbio A, Cervantes F, Isola I M, Vannucchi A M, Guglielmelli P, Rambaldi A, Finazzi G, Barosi G, Barbui T

机构信息

Hematology division, A.O. Papa Giovanni XXIII, Bergamo, Italy.

Research Foundation, A.O. Papa Giovanni XXIII, Bergamo, Italy.

出版信息

Leukemia. 2015 May;29(5):1209-10. doi: 10.1038/leu.2014.343. Epub 2014 Dec 8.

DOI:10.1038/leu.2014.343
PMID:25482134
Abstract
摘要

相似文献

1
CALR mutation, MPL mutation and triple negativity identify patients with the lowest vascular risk in primary myelofibrosis.CALR 突变、MPL 突变和三阴性可识别原发性骨髓纤维化中血管风险最低的患者。
Leukemia. 2015 May;29(5):1209-10. doi: 10.1038/leu.2014.343. Epub 2014 Dec 8.
2
Somatic mutations of calreticulin in myeloproliferative neoplasms.髓系增殖性肿瘤中的钙网织蛋白体细胞突变。
N Engl J Med. 2013 Dec 19;369(25):2379-90. doi: 10.1056/NEJMoa1311347. Epub 2013 Dec 10.
3
Mutation status of essential thrombocythemia and primary myelofibrosis defines clinical outcome.原发性血小板增多症和原发性骨髓纤维化的突变状态决定临床结局。
Haematologica. 2016 Apr;101(4):e129-32. doi: 10.3324/haematol.2015.138958. Epub 2016 Jan 14.
4
Essential thrombocythaemia with mutation in : clinicopathological correlation and comparison with 2V617F-mutated and mutated genotypes.伴有 JAK2 V617F 突变的原发性血小板增多症：临床病理相关性及与 JAK2 V617F 突变和突变基因型的比较
J Clin Pathol. 2018 Nov;71(11):975-980. doi: 10.1136/jclinpath-2018-205227. Epub 2018 Jun 22.
5
JAK2 V617F, MPL, and CALR Mutations in Korean Patients with Essential Thrombocythemia and Primary Myelofibrosis.韩国原发性血小板增多症和原发性骨髓纤维化患者的JAK2 V617F、MPL及CALR突变
J Korean Med Sci. 2015 Jul;30(7):882-8. doi: 10.3346/jkms.2015.30.7.882. Epub 2015 Jun 10.
6
Analysis of phenotype and outcome in essential thrombocythemia with CALR or JAK2 mutations.伴有CALR或JAK2突变的原发性血小板增多症的表型与预后分析。
Haematologica. 2015 Jul;100(7):893-7. doi: 10.3324/haematol.2014.118299. Epub 2015 May 1.
7
Calreticulin mutation profile in Indian patients with primary myelofibrosis.印度原发性骨髓纤维化患者的钙网蛋白突变谱
Hematology. 2015 Dec;20(10):567-70. doi: 10.1179/1607845415Y.0000000018. Epub 2015 May 11.
8
Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis.分子注释的原发性血小板增多症、真性红细胞增多症和骨髓纤维化的长期生存及原始细胞转化
Blood. 2014 Oct 16;124(16):2507-13; quiz 2615. doi: 10.1182/blood-2014-05-579136. Epub 2014 Jul 18.
9
Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis.JAK2、CALR或MPL驱动基因突变在原发性骨髓纤维化中的临床效应
Blood. 2014 Aug 14;124(7):1062-9. doi: 10.1182/blood-2014-05-578435. Epub 2014 Jul 1.
10
Calreticulin variant stratified driver mutational status and prognosis in essential thrombocythemia.钙网织蛋白变异体分层驱动基因突变状态和预后在原发性血小板增多症。
Am J Hematol. 2016 May;91(5):503-6. doi: 10.1002/ajh.24338. Epub 2016 Apr 4.

引用本文的文献

1
Impact of somatic gene mutations on the risk of thrombosis in myelofibrosis.体细胞基因突变对骨髓纤维化患者血栓形成风险的影响。
Leukemia. 2024 Nov;38(11):2483-2486. doi: 10.1038/s41375-024-02389-2. Epub 2024 Aug 30.
2
Clinical Characteristics and Outcomes of Patients with Primary and Secondary Myelofibrosis According to the Genomic Classification Using Targeted Next-Generation Sequencing.根据靶向二代测序的基因组分类，原发性和继发性骨髓纤维化患者的临床特征及预后
Cancers (Basel). 2023 Jul 31;15(15):3904. doi: 10.3390/cancers15153904.
3
Molecular Genetics of Thrombotic Myeloproliferative Neoplasms: Implications in Precision Oncology.

本文引用的文献

1
Calreticulin mutation does not modify the IPSET score for predicting the risk of thrombosis among 1150 patients with essential thrombocythemia.钙网蛋白突变不会改变1150例原发性血小板增多症患者中用于预测血栓形成风险的IPSET评分。
Blood. 2014 Oct 16;124(16):2611-2. doi: 10.1182/blood-2014-08-596676.
2
Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis.分子注释的原发性血小板增多症、真性红细胞增多症和骨髓纤维化的长期生存及原始细胞转化
Blood. 2014 Oct 16;124(16):2507-13; quiz 2615. doi: 10.1182/blood-2014-05-579136. Epub 2014 Jul 18.
3
Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis.
血栓性骨髓增殖性肿瘤的分子遗传学：对精准肿瘤学的启示
Diagnostics (Basel). 2023 Jan 3;13(1):163. doi: 10.3390/diagnostics13010163.
4
Prediction of thrombosis in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study on 1258 patients.预测真性红细胞增多症后和特发性血小板增多症后骨髓纤维化中的血栓形成：一项对 1258 例患者的研究。
Leukemia. 2022 Oct;36(10):2453-2460. doi: 10.1038/s41375-022-01673-3. Epub 2022 Aug 30.
5
Cardiovascular Disease in Myeloproliferative Neoplasms: State-of-the-Art Review.骨髓增殖性肿瘤中的心血管疾病：最新综述
JACC CardioOncol. 2022 Jun 21;4(2):166-182. doi: 10.1016/j.jaccao.2022.04.002. eCollection 2022 Jun.
6
Polymorphism Contributes to -Mutation Susceptibility and Is Associated with Low Risk of Deep Vein Thrombosis in Primary Myelofibrosis.多态性与基因突变易感性相关，并与原发性骨髓纤维化患者深静脉血栓形成的低风险有关。
TH Open. 2021 Nov 9;5(4):e513-e520. doi: 10.1055/s-0041-1739293. eCollection 2021 Oct.
7
The Contemporary Approach to CALR-Positive Myeloproliferative Neoplasms.CALR 阳性骨髓增殖性肿瘤的当代治疗方法。
Int J Mol Sci. 2021 Mar 25;22(7):3371. doi: 10.3390/ijms22073371.
8
The Genetic Basis of Primary Myelofibrosis and Its Clinical Relevance.原发性骨髓纤维化的遗传学基础及其临床意义。
Int J Mol Sci. 2020 Nov 24;21(23):8885. doi: 10.3390/ijms21238885.
9
Murine Models of Myelofibrosis.骨髓纤维化的小鼠模型
Cancers (Basel). 2020 Aug 23;12(9):2381. doi: 10.3390/cancers12092381.
10
Impact of Tumor Genomic Mutations on Thrombotic Risk in Cancer Patients.肿瘤基因组突变对癌症患者血栓形成风险的影响
Cancers (Basel). 2020 Jul 19;12(7):1958. doi: 10.3390/cancers12071958.
JAK2、CALR或MPL驱动基因突变在原发性骨髓纤维化中的临床效应
Blood. 2014 Aug 14;124(7):1062-9. doi: 10.1182/blood-2014-05-578435. Epub 2014 Jul 1.
4
Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia.钙网织蛋白突变对原发性血小板增多症的临床和血液学表型及预后的影响。
Blood. 2014 Mar 6;123(10):1552-5. doi: 10.1182/blood-2013-11-538983. Epub 2013 Dec 26.
5
JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes.JAK2 或 CALR 突变状态定义了具有显著不同临床过程和结局的特发性血小板增多症亚型。
Blood. 2014 Mar 6;123(10):1544-51. doi: 10.1182/blood-2013-11-539098. Epub 2013 Dec 23.
6
Thrombosis in primary myelofibrosis: incidence and risk factors.原发性骨髓纤维化中的血栓形成：发生率和危险因素。
Blood. 2010 Jan 28;115(4):778-82. doi: 10.1182/blood-2009-08-238956. Epub 2009 Nov 20.